Pfizer settles dispute with workers over Irungattukottai plant closure

In early 2019, Pfizer had decided to shut down two of its Indian manufacturing plants — Irungattukottai (Chennai) and Aurangabad (Maharashtra)

October 15, 2020 04:43 pm | Updated 04:43 pm IST - CHENNAI

Industrial Tribunal, Tamil Nadu has closed the dispute between pharma giant Pfizer Healthcare India Private Limited and a section of its workers, after the parties reached a settlement agreement. The dispute relates to closure of the company’s manufacturing plant in Irungattukottai and cessation of 270 workers.

In early 2019, Pfizer had decided to shut down two of its Indian manufacturing plants — Irungattukottai (Chennai) and Aurangabad (Maharashtra) — owing to lack of commercial viability. The manufacturing plants had come under Pfizer's fold, after its acquisition of Hospira, a provider of injectable drugs and infusion technologies in 2015.

Podhu Thozhilalar Sangam had raised a dispute before the Deputy Commissioner of Labour Sriperumbudur with regard to cessation of employment of 270 workmen. The negotiations talks failed and the dispute was referred to the Industrial Tribunal, Tamil Nadu, according to court documents.

After the submission of the failure report, both the parties said they have entered into a settlement with regard to the said dispute and the claims of the members of the Petitioner Union have also been settled, Industrial Tribunal noted.

As per the settlement reached on February 6, 2020, Pfizer paid members of the union about ₹4.67 crore. The Industrial Tribunal recorded the settlement and disposed of the case.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.